Written questions by Brown-Fuller.

What steps he is taking to review the quality and effectiveness of supported living services to ensure providers deliver the level of care for which they are commissioned.

Awaiting answer.

If he will take steps to help support families with the cost of infant formula.

Awaiting answer.

What steps he is taking to increase employment opportunities for newly qualified paramedics a) nationally and b) in Chichester constituency.

Awaiting answer.

What plans he has to support structured recruitment pathways for newly qualified paramedics entering the ambulance workforce.

Awaiting answer.

What steps he is taking to help ensure NHS ambulance trusts have sufficient funding to recruit newly qualified paramedics.

Awaiting answer.

What steps he is taking to address supply issues of Ramipril.

Awaiting answer.

What steps he is taking to improve the resilience of critical hospital infrastructure against extreme heat events a) nationally and b) in Chichester constituency.

Awaiting answer.

What steps his Department is taking to ensure that patients and their families are informed about tissue freezing options prior to surgery where clinically appropriate.

Awaiting answer.

What steps he is taking to improve access to continence care services for residents in Chichester constituency.

Integrated care boards (ICBs) are responsible for commissioning continence services in their areas. These services include assessment, treatment, and, where clinically appropriate, the supply of continence products.For Chichester residents, the Sussex Com...

What assessment he has made of the (a) consistency and (b) quality of continence product procurement across NHS England.

The Department updated the guidance for the products listed under Part IX of the drug tariff last year to introduce a process in which existing products, including continence products, re-apply to remain listed and are assessed by an expert panel, includi...

Whether he plans to bring forward legislative proposals to remove the requirement for three miscarriages before women are routinely offered support following pregnancy loss.

Awaiting answer.

What assessment he has made of the adequacy of access to miscarriage investigation and support services for patients in the Chichester constituency.

No assessment has been made of the adequacy of access to miscarriage services in the Chichester constituency.The University Hospitals Sussex NHS Foundation Trust operates a recurrent miscarriage clinic across all its sites, including at St Richard’s Hospi...

What assessment he has made of the level of support available to children with situational mutism in Chichester constituency.

The Government recognises that, for children and young people in distress or experiencing mental health difficulties, such as situational mutism, timely access to high-quality, early support is essential.The 10-Year Health Plan sets out ambitious plans to...

What assessment her Department has made of the adequacy of NHS pathways for patients with Long Covid, in particular the extent to which current service structures allow for an overall or holistic c

The commissioning of services for Long Covid is the responsibility of integrated care boards, which should be in line with NHS England’s commissioning guidance for post-COVID services, which sets out a blueprint for best practice in supporting people with...

What assessment he has made of the effectiveness of the Multi‑Specialty Recruitment Assessment for specialties beyond General Practice; and what assessment he has made of the potential impact of its use on applicant numbers in those specialties.

Awaiting answer.

What steps he is taking to (a) reduce waiting times for Parkinson's diagnosis and (b) help attract, train and retain specialist healthcare professionals for Parkinson’s.

Awaiting answer.

What steps his Department is taking to a) secure alternative treatments for people at risk of adrenal crisis following the discontinuation of hydrocortisone sodium phosphate solution and b) help ensure that people with adrenal insufficiency have timely access to appropriate emergency steroid treatment.

I refer the Hon. Member to the answer I gave to the Hon. Member for Isle of Wight West on 22 April 2026 to Question 126862.

What steps he is taking to improve access to cardiac screening for young people.

The Government recognises how worrying heart health can be for the families of young people. That is why the National Health Service already offers cardiac tests for young people who present with symptoms that could indicate a cardiac issue.However, testing young people without symptoms would be classed as a screening programme. It is vital that screening policy is based on robust scientific evidence, as screening can also cause harm.In considering whether any screening programme should be introduced, the Government is guided by the independent scientific advice of the UK National Screening Committee (UK NSC). The UK NSC makes its recommendations based on internationally recognised criteria and a rigorous evidence review and consultation process. Where the committee is confident that offering screening provides more good than harm, they recommend a screening programme.The UK NSC last reviewed screening for the conditions associated with sudden cardiac death in people under the age of 39 years old in 2019. The conclusion of that review was that population screening should not be offered, as research showed that current tests are not accurate enough to use on young people with no symptoms.Current evidence suggests that introducing population-level screening for sudden cardiac death would cause harm by misdiagnosing some people, which could lead to some people being prescribed medication that they don’t need or undergoing medical procedures that they don’t need, such as having an implantable defibrillator fitted. It could lead to people living in fear of sudden cardiac death when they’re not at risk, and potentially making life-changing decisions, such as giving up exercise, which could have a negative long-term impact on their health.The UK NSC is due to open a public consultation to seek comments from members of the public and stakeholders on screening for the conditions associated with sudden cardiac death later this spring, and we would encourage those with an interest to contribute.

What steps he is taking to ensure that brand‑specific prescribing is matched by adequate supply and distribution arrangements.

Decisions about what medicines to prescribe, including whether to prescribe by brand name or generically, are clinical decisions made following discussion with a patient.Where a prescriber specifies a particular brand or supplier because it is clinically necessary, for example due to side effects or allergies, pharmacies are required to dispense that specific product.Medicine supply chains are complex, global, and highly regulated and there are a number of reasons why supply can be disrupted, many of which are not specific to the United Kingdom and outside of Government control, including manufacturing difficulties, access to raw materials, sudden demand spikes, or distribution issues and regulatory issues. There are approximately 14,000 licensed medicines and the overwhelming majority are in good supply.While we can’t always prevent supply issues from occurring, we have a range of well-established processes and tools to manage them when they arise and mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals including pharmacists, so they can advise and support their patients.The Department monitors and manages medicine supply at a national level so that stocks remain available to meet regional and local demand.

What assessment he has made of the potential impact of NICE's severity modifier on access to drugs for secondary breast cancer patients.

I refer the Hon. Member to the answer given on 3 March 2026 to Question 114336.